peppersite
Metabolic supportsubcutaneous

Tesamorelin

Tesamorelin is a stabilized version of growth hormone-releasing hormone (GHRH) and the only GHRH peptide with FDA approval. It has been studied mainly in people with HIV, for reducing deep belly fat and liver fat and for its effects on the growth hormone system.

Researched for
Metabolic HealthBody CompositionCognitive Support

At a glance

Type
Metabolic support
Given by
subcutaneous
Evidence
Not yet audited here; the reference library calls it established
Reported amount
2 mg per Peptide Dosing Protocols. All 4 sources

How much to draw

Full calculator →
Your draw
–units
Fill in the three numbers to see the draw.
Amount per dose

Opened on 2 mg, the figure Peptide Dosing Protocols reports for Tesamorelin. A reported amount, not a recommendation. Change any number to match the vial in your hand. How to reconstitute a vial.

What sources report

Reference, not a recommendation

These are figures published elsewhere, reproduced with their source. Peppersite does not recommend an amount for Tesamorelin or for anything else, and nothing below has been checked against the study it came from.

1-2 mg SC daily at bedtime
Frequency
once daily at bedtime12+ weeks · Continuous per provider direction
Route
subcutaneous
Reported by
Commonly published practitioner dosing range - provider confirmation required.
2 mg
Frequency
Once daily
Route
subcutaneous
Reported by
Peptide Protocol Wiki
Standard: 2 mg once a day
Frequency
Once daily26 weeks · Cycle length Planning note 4 weeks 6 vials (10 mg) 28 daily doses needed.
Route
Subcutaneous injection in the abdomen only
Reported by
Peptide Dosing Protocols
What it saysHalf-life: Half-Life Tesamorelin 26-38 minutes Sermorelin 11-12 minutes CJC-1295(DAC) ~6-8 days Fe. The standard dosing for Tesamorelin is 2 mg administered once daily.
Fat loss stacking reference: 200 mcg (0.2 mg) fasted morning paired with AOD-9604 300 mcg. Cited for visceral fat targeting with Mod GRF 1-29 as a pulse-enhancing partner.
Frequency
Daily in stack contexts · Morning, fasted
Route
subcutaneous
Reported by
Peptide Therapy Reference Text
What it saysAug 2026), secondary reference; provider confirmation required.
Reconstitution, as reported
  • Commonly 2 mg vials · Reconstitute with sterile/bacteriostatic water
  • Reconstitute with bacteriostatic water
Not yet audited

We have not published an audit on Tesamorelin. Everything below is reference material, not our own reading of the literature, treat it as a starting point for questions, not as a grade.

How it is thought to work

Tesamorelin tells the pituitary gland to release more of the body's own growth hormone in its normal pulsing rhythm rather than as a constant flood, and the liver then makes more IGF-1, which carries out many of the downstream effects. That rise drives the breakdown of visceral fat, the deep fat around the organs, more than fat under the skin, and lowers fat built up in the liver. Researchers describe it as binding GHRH receptors and switching on the cAMP and PKA signaling pathways, leaving the brain's normal feedback control intact. The direct trial evidence is in HIV-associated populations, so use in other groups rests on extrapolation rather than large randomized trials.

In technical termsGHRH receptor agonist; GH axis modulation.

What we don't know

Outside HIV: the direct trial evidence is in people with HIV. Use in other groups rests on extrapolation, not large randomized trials.

Performance and body composition in healthy adults: a review covered in our audit says growth hormone peptides lack regulatory approval for physique or performance uses and that those benefits are uncertain. The audit adds that the groups studied for tesamorelin were not healthy adults.

Reported side effects

Seen in studies: reactions at the injection site, including redness, itching, pain, swelling and rash, were the most common, occurring in 50.7 percent of tesamorelin users versus 21.4 percent on placebo in one Phase 3 trial and 30.0 percent versus 24.1 percent in the other. Swelling from fluid shifts occurred in about 9.9 percent versus 5.8 percent on placebo, and muscle aches in 3.7 to 7.7 percent versus 1.6 to 2.2 percent, mostly mild to moderate. Joint pain was also reported. More tesamorelin users had raised HbA1c, a three-month average blood sugar marker, than placebo users. About half of participants developed anti-tesamorelin IgG antibodies after 26 to 52 weeks, with similar visceral fat and IGF-1 effects whether or not antibodies appeared.

Not ruled out: IGF-1 is expected to rise, and persistently very high levels, for example sustained above 3 SDS, are flagged as needing clinician review.

Who should avoid it

People with active cancer of any type: listed as a contraindication on the FDA label.

People who are pregnant or planning pregnancy: listed as a contraindication, and the label says to stop tesamorelin if pregnancy is suspected.

People who are breastfeeding: it can cross into breast milk.

People with a known allergy to tesamorelin or to mannitol, an inactive ingredient: listed as a contraindication.

People with major problems of the hypothalamus or pituitary gland, the brain areas that control hormone release: listed as a contraindication.

People with type 2 diabetes or raised blood sugar: growth hormone can affect glucose levels, and the label advises checking blood sugar before starting and during use, so this group is flagged for careful clinician review.

People with a history of cancer: flagged as needing careful clinician review before starting.

People with eye conditions such as diabetic retinopathy: flagged as needing careful clinician review before starting.

What gets monitored

Check blood sugar before starting and at intervals during use. (reported by Peptide Dosing Protocols)

Regulatory status

FDA approval: tesamorelin, sold as Egrifta, was approved by the FDA in November 2010 for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. The reference entry calls it the only growth hormone-releasing hormone peptide with current FDA approval.

Off-label use: use for any other reason is off-label. The FDA label lists contraindications that include active cancer, pregnancy, and major problems of the hypothalamus or pituitary gland.

Checked: November 2026.

Common questions

How is tesamorelin dosed in the label?

Sources report that tesamorelin is used at its full amount from day one, with no gradual ramp-up. The FDA approval covers adults with HIV-associated lipodystrophy, and use for anything else is off-label.

What is tesamorelin's half-life?

Its half-life is reported as about 26 to 38 minutes. That short window fits the body's natural pulsing pattern of growth hormone release.

Is tesamorelin FDA-approved?

Yes. It was approved in November 2010 for reducing excess abdominal fat in adults with HIV. It is the only GHRH peptide with current FDA approval.

What are the most common side effects of tesamorelin?

Reactions at the injection site are the most common, reported in 30.0 to 50.7 percent of users across the two Phase 3 trials. Fluid retention, joint pain and muscle aches were also reported, mostly mild to moderate.

How is tesamorelin reconstituted?

That depends on the vial size and how much water is added. The calculator on this page works out the draw for any combination, and the reconstitution guide covers the steps.

How much bacteriostatic water is reported for tesamorelin?

That depends on the vial size and how much water is added. The calculator on this page works out the draw for any combination, and the reconstitution guide covers the steps.

Open the reconstitution calculator →

What results have been reported with tesamorelin?

Phase 3 trials reported visceral fat reductions of roughly 12 to 20 percent over 26 weeks, with figures of about 15.2 percent and 11.7 percent against placebo in the two trials. A Lancet HIV study reported about 32 percent less liver fat and a lower rate of scarring progression at 12 months, and effects trended back toward baseline after stopping.

How does tesamorelin compare to sermorelin and CJC-1295?

Tesamorelin is the only one of the three with current FDA approval and Phase 3 trial data showing visceral fat reduction. Its direct trial evidence is in HIV-associated populations.

Sources

  1. 01Falutz J, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: pooled analysis of two multicenter Phase 3 trials with safety extension data. Journal of Clinical Endocrinology & Metabolism (2010)
  2. 02Stanley TL, Fourman LT, Feldpausch MN, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV (2019)
  3. 03Fourman LT, Stanley TL, et al. Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD. JCI Insight (2020)
  4. 04Fourman LT, Stanley TL, et al. Delineating tesamorelin response pathways in HIV-associated NAFLD using a targeted proteomic and transcriptomic approach. Scientific Reports (2021)
  5. 05Grinspoon S, et al. Effects of a Growth Hormone-Releasing Hormone Analog on Endogenous GH Pulsatility and Insulin Sensitivity in Healthy Men. Journal of Clinical Endocrinology & Metabolism (2011)
  6. 06Ishida J, et al. Growth hormone secretagogues: history, mechanism of action, and clinical development. JCSM Rapid Communications (2020)
  7. 07U.S. Food and Drug Administration Egrifta SV (tesamorelin) prescribing information. FDA (2024)
  8. 08U.S. Food and Drug Administration Egrifta WR (tesamorelin) prescribing information. FDA (2025)
  9. 09Drugs.com Tesamorelin Monograph for Professionals. Drugs.com (2025)
  10. 10National Institutes of Health LiverTox: Tesamorelin. NCBI Bookshelf (2023)
  11. 11ClinicalTrials.gov Tesamorelin Effects on Liver Fat and Histology in HIV (NCT02196831). ClinicalTrials.gov (2024)
  12. 12Falutz J, McLaughlin T, et al. Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors. AIDS (2024)

The reference sections on this page come from a compound library we import, not from our own review of the studies. Our own evidence grade appears only where an audit is linked. Research use only; nothing here is medical advice or a protocol.

Studied for the same things
Advanced Recomp Stack

The Advanced Recomp Stack is a combination of three research peptides: retatrutide, CJC-1295 (No DAC) and ipamorelin, used as separate vials or with the last two pre-blended. It is discussed for fat loss with lean-mass support, and no published human trial has tested all three together.

AOD-9604

AOD-9604 is a lab-made chain of 16 amino acids copied from the tail end of human growth hormone, sold under the names HGH Fragment 176-191 and hexadecapeptide 177-191. It was studied for fat metabolism in animals and in six human trials of roughly 900 people, and the largest trial missed its main goal.

Cagrilintide / Retatrutide

Cagrilintide / Retatrutide is a combination of cagrilintide, an amylin analog, and retatrutide, a triple GLP-1, GIP and glucagon agonist, sold pre-blended in one vial or as separate vials. It is discussed for weight management, and no clinical trial has tested the two together.

Cagrilintide / Tirzepatide

Cagrilintide / Tirzepatide is a combination of cagrilintide, an amylin analog, and tirzepatide, a dual GIP and GLP-1 agonist, each given once weekly from its own vial. It is discussed for weight management, with one study in obese rats and no human trial of the two together.

CagriSema

CagriSema is an investigational fixed-dose combination of cagrilintide, a long-acting amylin analog, and semaglutide, a GLP-1 receptor agonist, given once weekly. It has been studied for weight management in people in Phase 3 trials and is not FDA-approved as of June 2026.

CJC-1295

CJC-1295 No DAC, also called Modified GRF 1-29, is a short-acting lab-made copy of growth-hormone-releasing hormone (GHRH), the body's signal to release growth hormone. Published human studies cover the parent CJC-1295 compound, and no large trial has tested the No DAC version.